Stereotactic body radiotherapy versus hepatic resection for recurrent small hepatocellular carcinoma: A post-hoc analysis with propensity score adjustment from two randomized trials - PubMed
3 hours ago
- #Stereotactic body radiotherapy
- #Surgical resection
- #Hepatocellular carcinoma
- Stereotactic body radiotherapy (SBRT) and hepatic resection were compared for treating recurrent small hepatocellular carcinoma (sHCC).
- The study included 158 patients from two randomized trials, with 83 receiving SBRT and 75 undergoing resection.
- 3-year local progression-free survival (LPFS) rates were 84.3% for SBRT and 76.8% for resection, showing no significant difference (P = 0.311).
- Median progression-free survival was 37.6 months for SBRT and 26.3 months for resection, with no significant difference (P = 0.287).
- 3-year overall survival rates were 90.3% for SBRT and 81.1% for resection, with no significant difference (P = 0.118).
- Adverse event incidences were similar between both groups (P = 0.695).
- SBRT demonstrated comparable tumor control and long-term outcomes to resection, suggesting it as a potential alternative for recurrent sHCC.